Truven Health Analytics' Tool to Improve Oncology Outcomes Research

Truven Health Analytics™ today announced it has successfully linked electronic medical records (EMR) and administrative claims data with significant volume to power oncology-focused outcomes research studies. This de-identified data set, the newest addition to the MarketScan® research databases, provides a unique ability for researchers to better understand total healthcare costs, co-morbidities, adverse events, and outcomes for cancer patients by treatment phase, biomarker status, and tumor stage.

“It is exciting to see the pace of development for break-through oncology treatments. As these products come to market, researchers require real-world data to conduct high quality investigations that demonstrate the value of these new treatments.” said Stacey Long, vice president and general manager at Truven Health Analytics. “Payers, providers, and patients want to understand how new treatments affect not only health outcomes, but also overall costs. To do this, researchers need patient-level data that include not only the robust clinical data offered by an oncology EMR, but also the same patient’s claims data to understand associated healthcare costs and the full spectrum of a patient’s care beyond that provided by their oncologist. We are delighted to be able to offer this ground-breaking capability to the healthcare research community.”

Read the press release here:

Source: Digital Journal

Related Videos
Jeremy Wigginton, MD
Screenshot of Eleonora Lad, MD, PhD, smiling
Debra Patt, MD, PhD, MBA, Executive Vice President, Texas Oncology
Ben Jones, Vice President of Government Relations and Public Policy, US Oncology Network
Manmeet Ahluwalia, MD, MBA.
Nicolas Ferreyros, BA, managing director, The Community Oncology Alliance
Susan Sabo-Wagner, MSN, RN, OCN, Oncology Consultants
Screenshot of Sancy Leachman, MD, PhD, smiling
Tochi M. Okwuosa, DO, Rush University Medical Center
Screenshot of Emma Guttman-Yassky, MD, PhD, smiling
Related Content
© 2023 MJH Life Sciences
All rights reserved.